RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that the Klinikum Esslingen, a hospital in southern Germany close to Stuttgart, has entered into an agreement to lease and utilize a Senhance® System. The Senhance System has been installed at the hospital facility and cases are expected to begin shortly. This placement is one of the two placements referenced in the Company’s January 6, 2020 press release.
Klinikum Esslingen is a major German hospital that serves as the academic teaching hospital of the University of Tübingen. The facility has more than 660 beds and performs more than 9,000 surgical interventions each year.
The Senhance® Surgical System is the first and only digital laparoscopic platform designed to maintain laparoscopic MIS standards while providing digital benefits such as haptic feedback, robotic precision, comfortable ergonomics, advanced instrumentation including, 3 mm microlaparoscopic instruments, eye-sensing camera control and reusable standard instruments to help maintain per-procedure costs similar to traditional laparoscopy.
“We are committed to support and grow the outstanding minimally invasive surgical program of Klinikum Esslingen with the addition of a Senhance System,” said Anthony Fernando, president and chief executive officer at TransEnterix. “We continue to see strong momentum in Germany, and the expansion into such a prestigious hospital as the Klinikum Esslingen is a significant milestone in the advancement of digital laparoscopy with Senhance in Europe.”
“We have created a strong, multidisciplinary program in minimally invasive surgery at our hospital,” said Professor Dr. Ludger Staib, chief physician of the clinic for general and visceral surgery at the Klinikum Esslingen. “We believe modern technology can help offer our patients the most precise and least invasive surgery possible, and we appreciate the ability to build on our strong existing minimally invasive program with the Senhance that will allow for maximum precision, visualization and control during delicate surgeries.”
About TransEnterix
TransEnterix is a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options in today's value-based healthcare environment. The Company is focused on the commercialization of the Senhance Surgical System, which digitizes laparoscopic minimally invasive surgery. The system allows for robotic precision, haptic feedback, surgeon camera control via eye sensing and improved ergonomics while offering responsible economics. The Senhance Surgical System is available for sale in the US, the EU, Japan and select other countries.
Back to HCB News
